HK Stock Market Move | IMMUNEONCO-B(01541) opened more than 4% higher. The core product IMM01 completed the first patient dosing in Phase III clinical trial.

IMMUNEONCO-B (01541) opened over 4% higher and, as of the writing, rose 4.19% to 9.7 Hong Kong dollars with a trading volume of 3.4551 million Hong Kong dollars. On the news front, Yiming Angke announced that the group's core product IMM01 (Tirapazamine) in combination with azacitidine has successfully completed the first patient dosing in a Phase III clinical trial for the first-line treatment of chronic myelomonocytic leukemia (CMML). This is the world's first Phase III clinical study for the first-line treatment of CMML targeting differentiation cluster 47 (CD47). In addition, Yiming Angke announced at the end of last month that the Phase Ib clinical trial of IMM0306 for the treatment of Systemic Lupus Erythematosus (SLE) has successfully completed the first patient dosing. Developed independently by the group, IMM0306 is a dual-specificity molecule targeting CD47 and CD20, making it the world's first CD47 and CD20 dual-specificity molecule to enter clinical stage. As of the date of this announcement, the group holds global intellectual property and commercialization rights for IMM0306.